Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blinatumomab for infant acute lymphoblastic leukemia.
Clesham K, Rao V, Bartram J, Ancliff P, Ghorashian S, O'Connor D, Pavasovic V, Rao A, Samarasinghe S, Cummins M, Malone A, Patrick K, Bonney D, James B, Gibson B, Vora A. Clesham K, et al. Among authors: james b. Blood. 2020 Apr 23;135(17):1501-1504. doi: 10.1182/blood.2019004008. Blood. 2020. PMID: 32043146 Free article. No abstract available.
High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group.
Gassas A, Sivaprakasam P, Cummins M, Breslin P, Patrick K, Slatter M, Skinner R, Shenton G, Gibson B, Lawson S, Petterson T, Potter M, James B, Hough R, Hiwarkar P, Vora A, Veys P, De La Fuente J, Wynn R, Amrolia P. Gassas A, et al. Among authors: james b. Bone Marrow Transplant. 2018 Sep;53(9):1165-1169. doi: 10.1038/s41409-018-0157-x. Epub 2018 Mar 15. Bone Marrow Transplant. 2018. PMID: 29545594
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, Gibson B, Goulden N, Kearns P, James B, Kirkwood AA, Lancaster D, Madi M, McMillan A, Motwani J, Norton A, O'Marcaigh A, Patrick K, Bhatnagar N, Qureshi A, Richardson D, Stokley S, Taylor G, van Delft FW, Moppett J, Harrison CJ, Samarasinghe S, Vora A. Moorman AV, et al. Among authors: james b. Br J Haematol. 2020 Dec;191(5):844-851. doi: 10.1111/bjh.17093. Epub 2020 Sep 14. Br J Haematol. 2020. PMID: 32926422 Free article. Clinical Trial.
Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab-Flu-Cy: the UK experience.
Bernard F, Uppungunduri CRS, Meyer S, Cummins M, Patrick K, James B, Skinner R, Tewari S, Carpenter B, Wynn R, Veys P, Amrolia P; UK Paediatric BMT group. Bernard F, et al. Among authors: james b. Br J Haematol. 2021 May;193(4):804-813. doi: 10.1111/bjh.17418. Epub 2021 Apr 14. Br J Haematol. 2021. PMID: 33855694 Clinical Trial.
COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
Lucchini G, Furness C, Lawson S, Gibson B, Wynn R, Slatter M, Shillitoe B, James B, Carpenter B, Hough R, Amrolia P, de la Fuente J; UK and Ireland Paediatric BMT Group. Lucchini G, et al. Among authors: james b. Br J Haematol. 2021 Aug;194(4):e74-e77. doi: 10.1111/bjh.17547. Epub 2021 Jun 20. Br J Haematol. 2021. PMID: 34132400 Free PMC article. No abstract available.
T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy.
Horgan C, Mullanfiroze K, Rauthan A, Patrick K, Butt NA, Mirci-Danicar O, O'Connor O, Furness C, Deshpande A, Lawson S, Broderick V, Evans P, Gibson B, Roberts W, Ali S, Galani S, Kirkwood AA, Jovanovic J, Dillon R, Virgo P, James B, Rao K, Amrolia PJ, Wynn RF. Horgan C, et al. Among authors: james b. Blood Adv. 2023 May 23;7(10):2155-2165. doi: 10.1182/bloodadvances.2022009253. Blood Adv. 2023. PMID: 36649566 Free PMC article.
Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts.
Lum SH, James B, Ottaviano G, Ewins AM, Patrick K, Ali S, Carpenter B, Silva J, Tewari S, Furness C, Thomas A, Shenton G, Bonney D, Moppett J, Hambleton S, Gennery AR, Amrolia P, Gibson B, Hough R, Rao K, Slatter M, Wynn R. Lum SH, et al. Among authors: james b. Transplant Cell Ther. 2024 Mar;30(3):314.e1-314.e12. doi: 10.1016/j.jtct.2023.12.005. Epub 2023 Dec 14. Transplant Cell Ther. 2024. PMID: 38103787 Free article.
957 results